DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dianthus Therapeutics, Inc. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$74.54+2.45 (+3.40%)
Close on Oct 19, 2026
- Market cap
- $4.18B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
+$38.89 (+109.1%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Dianthus Therapeutics, Inc. /DE/ saw revenue fall 67.3% to $2.04M over fiscal 2025.
Revenue
$2.04M
-67.3% vs. a year earlier
Operating income
-$217.84M
TTM Q2 2026
EPS, diluted
-$4.15
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $4.18B
- P/E ratio
- –
- Price to sales
- 2051.28
- Price to book
- 3.56
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.04M
- Net income
- -$192.25M
- EPS, diluted
- -$4.15
- Book value per share
- $20.92
- Diluted shares
- 56M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$217.84M
Net income
-$192.25M
EPS, diluted
-$4.15
Free cash flow
–
Reported periodTrailing twelve months